Expression of nuclear insulin receptor substrate 1 in breast cancer

Diego Sisci, Catia Morelli, Cecilia Garofalo, Francesco Romeo, Lucio Morabito, Filomena Casaburi, Emilia Middea, Sandra Cascio, Elvira Brunelli, Sebastiano Andò, Eva Surmacz

Research output: Contribution to journalArticlepeer-review


Background: Insulin receptor substrate 1 (IRS-1), a cytoplasmic protein transmitting signals from the insulin and insulin-like growth factor 1 receptors, has been implicated in breast cancer. Previously, it was reported that IRS-1 can be translocated to the nucleus and modulate oestrogen receptor α (ERα) activity in vitro. However, the expression of nuclear IRS-1 in breast cancer biopsy specimens has never been examined. Aims: To assess whether nuclear IRS-1 is present in breast cancer and non-cancer mammary epithelium, and whether it correlates with other markers, especially ERα. Parallel studies were carried out for the expression of cytoplasmatic IRS-1. Methods: IRS-1 and ERα expression was assessed by immunohistochemical analysis. Data were evaluated using Pearson's correlation, linear regression and receiver operating characteristic analysis. Results: Median nuclear IRS-1 expression was found to be low in normal mammary epithelial cells (1.6%) and high in benign tumours (20.5%), ductal grade 2 carcinoma (11.0%) and lobular carcinoma (∼30%). Median ERα expression in normal epithelium, benign tumours, ductal cancer grade 2 and 3, and lobular cancer grade 2 and 3 were 10.5, 20.5, 65.0, 0.0, 80 and 15%, respectively. Nuclear IRS-1 and ERα positively correlated in ductal cancer (p

Original languageEnglish
Pages (from-to)633-641
Number of pages9
JournalJournal of Clinical Pathology
Issue number6
Publication statusPublished - Jun 2007

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Expression of nuclear insulin receptor substrate 1 in breast cancer'. Together they form a unique fingerprint.

Cite this